Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 1123

1.

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.

Younossi Z, Stepanova M, Omata M, Mizokami M, Walters M, Hunt S.

Health Qual Life Outcomes. 2017 Jan 31;15(1):25. doi: 10.1186/s12955-017-0598-8.

2.

Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients.

Nirei K, Matsumura H, Kumakawa M, Matsumoto N, Nakamura H, Yamagami H, Matsuoka S, Moriyama M.

Int J Med Sci. 2017 Jan 1;14(1):45-52. doi: 10.7150/ijms.17202.

3.

Incidence of HCV induced-Esophageal varices in Egypt: Valuable knowledge using data mining analysis.

Abdel-Aty M, Fouad M, Sallam MM, Elgohary EA, Ismael A, Nawara A, Hawary B, Tag-Adeen M, Khaled S.

Medicine (Baltimore). 2017 Jan;96(4):e5647. doi: 10.1097/MD.0000000000005647.

4.

Management of direct antiviral agent failures.

Buti M, Esteban R.

Clin Mol Hepatol. 2016 Dec;22(4):432-438. doi: 10.3350/cmh.2016.0107. Review.

5.

Survival benefits of interferon-based therapy in patients with recurrent hepatitis C after orthotopic liver transplantation.

Zanaga LP, Vigani AG, Angerami RN, Giorgetti A, Escanhoela CA, Ataíde EC, Boin IF, Stucchi RS.

Braz J Med Biol Res. 2017 Jan 9;50(1):e5540. doi: 10.1590/1414-431X20165540.

6.
7.

The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.

Young J, Weis N, Hofer H, Irving W, Weiland O, Giostra E, Pascasio JM, Castells L, Prieto M, Postema R, Lefevre C, Evans D, Bucher HC, Calleja JL.

BMC Infect Dis. 2017 Jan 7;17(1):45. doi: 10.1186/s12879-016-2106-x.

8.

Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.

Kim DY, Han KH, Jun B, Kim TH, Park S, Ward T, Webster S, McEwan P.

PLoS One. 2017 Jan 6;12(1):e0167770. doi: 10.1371/journal.pone.0167770.

9.

<i>PNPLA3</i> polymorphism increases risk for and severity of chronic hepatitis C liver disease.

Salameh H, Masadeh M, Al Hanayneh M, Petros V, Maslonka M, Nanda A, Singal AK.

World J Hepatol. 2016 Dec 18;8(35):1584-1592. doi: 10.4254/wjh.v8.i35.1584.

10.

Fibrosis in Chronic Hepatitis C: Correlation between Immunohistochemically-Assessed Virus Load with Steatosis and Cellular Iron Content.

Akl M, Hindawi AE, Mosaad M, Montasser A, Ray AE, Khalil H, Anas A, Atta R, Paradis V, Hadi AA, Hammam O.

Open Access Maced J Med Sci. 2016 Dec 15;4(4):578-584. doi: 10.3889/oamjms.2016.122.

11.

Chronic hepatitis C infection-induced liver fibrogenesis is associated with M2 macrophage activation.

Bility MT, Nio K, Li F, McGivern DR, Lemon SM, Feeney ER, Chung RT, Su L.

Sci Rep. 2016 Dec 21;6:39520. doi: 10.1038/srep39520.

12.

Severe Anemia with Hemoperitoneum as a First Presentation for Multinodular Hepatocellular Carcinoma: A Rare Event in Western Countries.

Swe T, Naing AT, Baqui A, Khillan R.

Case Reports Hepatol. 2016;2016:7082387. doi: 10.1155/2016/7082387.

13.

Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment.

Huang CF, Huang CY, Yeh ML, Wang SC, Chen KY, Ko YM, Lin CC, Tsai YS, Tsai PC, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, Yu ML.

EBioMedicine. 2017 Feb;15:81-89. doi: 10.1016/j.ebiom.2016.11.031.

14.

Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C.

Hernández-Bartolomé Á, López-Rodríguez R, Borque MJ, González-Moreno L, Real-Martínez Y, García-Buey L, Moreno-Otero R, Sanz-Cameno P.

World J Gastroenterol. 2016 Nov 28;22(44):9744-9751.

15.
16.

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection.

Sarrazin C, Castelli F, Andreone P, Buti M, Colombo M, Pol S, Calinas F, Puoti M, Olveira A, Shiffman M, Stern JO, Kukolj G, Roehrle M, Aslanyan S, Deng Q, Vinisko R, Mensa FJ, Nelson DR.

Clin Exp Gastroenterol. 2016 Nov 24;9:351-363.

17.

<i>IL28B</i> genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study.

Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, Rasmann N, Messinger D, Tatsch F, Bakalos G, Foster GR; Gen-C study group..

Springerplus. 2016 Nov 18;5(1):1990.

18.

Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection.

Cho J, Lee SS, Choi YS, Jeon Y, Chung JW, Baeg JY, Si WK, Jang ES, Kim JW, Jeong SH.

World J Gastroenterol. 2016 Nov 14;22(42):9427-9436.

19.

Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.

Weiler N, Zeuzem S, Welker MW.

World J Gastroenterol. 2016 Nov 7;22(41):9044-9056. Review.

20.

Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.

Gambato M, Caro-Pérez N, González P, Cañete N, Mariño Z, Lens S, Bonacci M, Bartres C, Sánchez-Tapias JM, Carrión JA, Forns X, Juan M, Pérez-Del-Pulgar S, Londoño MC.

PLoS One. 2016 Nov 18;11(11):e0166631. doi: 10.1371/journal.pone.0166631. Erratum in: PLoS One. 2017 Jan 20;12 (1):e0170913.

Items per page

Supplemental Content

Loading ...
Support Center